{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:36:17Z","timestamp":1792179377490,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T00:00:00Z","timestamp":1460419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T00:00:00Z","timestamp":1460419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Vaccines to protect against tuberculosis (TB) are urgently needed. We performed a case\u2013control analysis to identify immune correlates of TB disease risk in Bacille Calmette\u2013Guerin (BCG) immunized infants from the MVA85A efficacy trial. Among 53 TB case infants and 205 matched controls, the frequency of activated HLA-DR\n                    <jats:sup>+<\/jats:sup>\n                    CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells associates with increased TB disease risk (OR=1.828, 95% CI=1.25\u20132.68,\n                    <jats:italic>P<\/jats:italic>\n                    =0.002, FDR=0.04, conditional logistic regression). In an independent study of\n                    <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n                    -infected adolescents, activated HLA-DR\n                    <jats:sup>+<\/jats:sup>\n                    CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells also associate with increased TB disease risk (OR=1.387, 95% CI=1.068\u20131.801,\n                    <jats:italic>P<\/jats:italic>\n                    =0.014, conditional logistic regression). In infants, BCG-specific T cells secreting IFN-\u03b3 associate with reduced risk of TB (OR=0.502, 95% CI=0.29\u20130.86,\n                    <jats:italic>P<\/jats:italic>\n                    =0.013, FDR=0.14). The causes and impact of T-cell activation on disease risk should be considered when designing and testing TB vaccine candidates for these populations.\n                  <\/jats:p>","DOI":"10.1038\/ncomms11290","type":"journal-article","created":{"date-parts":[[2016,4,12]],"date-time":"2016-04-12T05:09:53Z","timestamp":1460437793000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":226,"title":["T-cell activation is an immune correlate of risk in BCG vaccinated infants"],"prefix":"10.1038","volume":"7","author":[{"given":"Helen A.","family":"Fletcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A.","family":"Snowden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Landry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7671-7305","authenticated-orcid":false,"given":"Wasima","family":"Rida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Satti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Matsumiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"O\u2019Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerabadran","family":"Dheenadhayalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Bogardus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Stockdale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Marsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Chomka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Harrington-Kandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zita-Rose","family":"Manjaly-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Naranbhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Stylianou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatoumatta","family":"Darboe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Penn-Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Nemes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Hatherill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Hussey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Mahomed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Tameris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Bruce","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem A.","family":"Hanekom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Scriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McShane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,12]]},"reference":[{"key":"BFncomms11290_CR1","doi-asserted-by":"publisher","first-page":"a2052","DOI":"10.1136\/bmj.a2052","volume":"337","author":"A Hawkridge","year":"2008","unstructured":"Hawkridge, A. et al. Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial. BMJ 337, a2052 (2008).","journal-title":"BMJ"},{"key":"BFncomms11290_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.280.5368.1432","volume":"280","author":"F Altare","year":"1998","unstructured":"Altare, F. et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280, 1432\u20131435 (1998).","journal-title":"Science"},{"key":"BFncomms11290_CR3","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1056\/NEJM199612263352604","volume":"335","author":"E Jouanguy","year":"1996","unstructured":"Jouanguy, E. et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 335, 1956\u20131961 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFncomms11290_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/immu.200390008","volume":"33","author":"EG Lichtenauer-Kaligis","year":"2003","unstructured":"Lichtenauer-Kaligis, E. G. et al. Severe Mycobacterium bovis BCG infections in a large series of novel IL-12 receptor beta1 deficient patients and evidence for the existence of partial IL-12 receptor beta1 deficiency. Eur. J. Immunol. 33, 59\u201369 (2003).","journal-title":"Eur. J. Immunol."},{"key":"BFncomms11290_CR5","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1056\/NEJM199612263352602","volume":"335","author":"MJ Newport","year":"1996","unstructured":"Newport, M. J. et al. A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection. N. Engl. J. Med. 335, 1941\u20131949 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFncomms11290_CR6","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1086\/338625","volume":"70","author":"C Picard","year":"2002","unstructured":"Picard, C. et al. Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds. Am. J. Hum. Genet. 70, 336\u2013348 (2002).","journal-title":"Am. J. Hum. Genet."},{"key":"BFncomms11290_CR7","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/S0140-6736(10)60409-6","volume":"375","author":"AD Harries","year":"2010","unstructured":"Harries, A. D. et al. The HIV-associated tuberculosis epidemic--when will we act? Lancet 375, 1906\u20131919 (2010).","journal-title":"Lancet"},{"key":"BFncomms11290_CR8","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1084\/jem.178.6.2243","volume":"178","author":"AM Cooper","year":"1993","unstructured":"Cooper, A. M. et al. Disseminated tuberculosis in interferon gamma gene-disrupted mice. J. Exp. Med. 178, 2243\u20132247 (1993).","journal-title":"J. Exp. Med."},{"key":"BFncomms11290_CR9","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.1084\/jem.178.6.2249","volume":"178","author":"JL Flynn","year":"1993","unstructured":"Flynn, J. L. et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178, 2249\u20132254 (1993).","journal-title":"J. Exp. Med."},{"key":"BFncomms11290_CR10","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.5588\/ijtld.12.0569","volume":"16","author":"MJ Brennan","year":"2012","unstructured":"Brennan, M. J., Stone, M. R. & Evans, T. A rational vaccine pipeline for tuberculosis. Int. J. Tuberc. Lung Dis. 16, 1566\u20131573 (2012).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFncomms11290_CR11","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1164\/rccm.201003-0334OC","volume":"182","author":"BM Kagina","year":"2010","unstructured":"Kagina, B. M. et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guerin vaccination of newborns. Am. J. Respir. Crit. Care Med. 182, 1073\u20131079 (2010).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"BFncomms11290_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021\u20131028 (2013).","journal-title":"Lancet"},{"key":"BFncomms11290_CR13","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1002\/sim.4780090710","volume":"9","author":"Y Hochberg","year":"1990","unstructured":"Hochberg, Y. & Benjamini, Y. More powerful procedures for multiple significance testing. Stat. Med. 9, 811\u2013818 (1990).","journal-title":"Stat. Med."},{"key":"BFncomms11290_CR14","first-page":"331","volume":"15","author":"H Mahomed","year":"2011","unstructured":"Mahomed, H. et al. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. Int. J. Tuberc. Lung Dis. 15, 331\u2013336 (2011).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"BFncomms11290_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/0090-1229(89)90188-8","volume":"52","author":"JV Giorgi","year":"1989","unstructured":"Giorgi, J. V. & Detels, R. T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin. Immunol. Immunopathol. 52, 10\u201318 (1989).","journal-title":"Clin. Immunol. Immunopathol."},{"key":"BFncomms11290_CR16","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1097\/QAD.0b013e3283601bad","volume":"27","author":"R Karim","year":"2013","unstructured":"Karim, R. et al. Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach. AIDS 27, 1473\u20131481 (2013).","journal-title":"AIDS"},{"key":"BFncomms11290_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00042560-199710010-00003","volume":"16","author":"Z Liu","year":"1997","unstructured":"Liu, Z. et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. 16, 83\u201392 (1997).","journal-title":"J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol."},{"key":"BFncomms11290_CR18","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1097\/00002030-200309050-00006","volume":"17","author":"MD Hazenberg","year":"2003","unstructured":"Hazenberg, M. D. et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17, 1881\u20131888 (2003).","journal-title":"AIDS"},{"key":"BFncomms11290_CR19","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/infdis\/jis941","volume":"207","author":"AP Soares","year":"2013","unstructured":"Soares, A. P. et al. Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J. Infect. Dis. 207, 1084\u20131094 (2013).","journal-title":"J. Infect. Dis."},{"key":"BFncomms11290_CR20","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1093\/infdis\/jis732","volume":"207","author":"L Wittkop","year":"2013","unstructured":"Wittkop, L. et al. Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. J. Infect. Dis. 207, 622\u2013627 (2013).","journal-title":"J. Infect. Dis."},{"key":"BFncomms11290_CR21","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1097\/00002030-199906180-00019","volume":"13","author":"TG Evans","year":"1999","unstructured":"Evans, T. G. et al. Expansion of the CD57 subset of CD8 T cells in HIV-1 infection is related to CMV serostatus. AIDS 13, 1139\u20131141 (1999).","journal-title":"AIDS"},{"key":"BFncomms11290_CR22","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cell.2014.12.020","volume":"160","author":"P Brodin","year":"2015","unstructured":"Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37\u201347 (2015).","journal-title":"Cell"},{"key":"BFncomms11290_CR23","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/cid\/cit790","volume":"58","author":"P Mangtani","year":"2014","unstructured":"Mangtani, P. et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin. Infect. Dis. 58, 470\u2013480 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"BFncomms11290_CR24","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1128\/CVI.05263-11","volume":"19","author":"AS de Almeida","year":"2012","unstructured":"de Almeida, A. S., Fiske, C. T., Sterling, T. R. & Kalams, S. A. Increased frequency of regulatory T cells and T lymphocyte activation in persons with previously treated extrapulmonary tuberculosis. Clin. Vaccine. Immunol. 19, 45\u201352 (2012).","journal-title":"Clin. Vaccine. Immunol."},{"key":"BFncomms11290_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1365-3083.2010.02496.x","volume":"73","author":"I Wergeland","year":"2011","unstructured":"Wergeland, I., Assmus, J. & Dyrhol-Riise, A. M. T regulatory cells and immune activation in Mycobacterium tuberculosis infection and the effect of preventive therapy. Scand. J. Immunol. 73, 234\u2013242 (2011).","journal-title":"Scand. J. Immunol."},{"key":"BFncomms11290_CR26","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1182\/blood.V82.9.2767.2767","volume":"82","author":"P Sansoni","year":"1993","unstructured":"Sansoni, P. et al. Lymphocyte subsets and natural killer cell activity in healthy old people and centenarians. Blood 82, 2767\u20132773 (1993).","journal-title":"Blood"},{"key":"BFncomms11290_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0531-5565(98)00058-8","volume":"34","author":"IM Rea","year":"1999","unstructured":"Rea, I. M., McNerlan, S. E. & Alexander, H. D. CD69, CD25, and HLA-DR activation antigen expression on CD3+ lymphocytes and relationship to serum TNF-alpha, IFN-gamma, and sIL-2R levels in aging. Exp. Gerontol. 34, 79\u201393 (1999).","journal-title":"Exp. Gerontol."},{"key":"BFncomms11290_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1006\/jtbi.1998.0734","volume":"193","author":"MD Kaufman","year":"1998","unstructured":"Kaufman, M. D. Do microbes with peptides mimicking myelin cause multiple sclerosis if the T cell response to their unique peptides is limited? J. Theor. Biol. 193, 691\u2013708 (1998).","journal-title":"J. Theor. Biol."},{"key":"BFncomms11290_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1046\/j.1365-2249.1999.00815.x","volume":"115","author":"T Messele","year":"1999","unstructured":"Messele, T. et al. Reduced naive and increased activated CD4 and CD8 cells in healthy adult Ethiopians compared with their Dutch counterparts. Clin. Exp. Immunol. 115, 443\u2013450 (1999).","journal-title":"Clin. Exp. Immunol."},{"key":"BFncomms11290_CR30","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1172\/JCI75429","volume":"124","author":"E Muyanja","year":"2014","unstructured":"Muyanja, E. et al. Immune activation alters cellular and humoral responses to yellow fever 17D vaccine. J. Clin. Invest. 124, 3147\u20133158 (2014).","journal-title":"J. Clin. Invest."},{"key":"BFncomms11290_CR31","doi-asserted-by":"publisher","unstructured":"Zak, D. E. et al. for other members of the ACS and GC6-74 cohort study teams. A prospective blood RNA signature for tuberculosis disease risk. Lancet http:\/\/dx.doi.org\/10.1016\/S0140-6736(15)01316-1 (23 March 2016).","DOI":"10.1016\/S0140-6736(15)01316-1"},{"key":"BFncomms11290_CR32","doi-asserted-by":"publisher","first-page":"S6-S","DOI":"10.1016\/j.jcv.2009.09.002","volume":"46","author":"MJ Cannon","year":"2009","unstructured":"Cannon, M. J. Congenital cytomegalovirus (CMV) epidemiology and awareness. J. Clin. Virol. 46, (Suppl 4)): S6-S\u201310 (2009).","journal-title":"J. Clin. Virol."},{"key":"BFncomms11290_CR33","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1097\/OLQ.0b013e3181644b70","volume":"35","author":"SA Staras","year":"2008","unstructured":"Staras, S. A. et al. Influence of sexual activity on cytomegalovirus seroprevalence in the United States, 1988\u20131994. Sex Transm. Dis. 35, 472\u2013479 (2008).","journal-title":"Sex Transm. Dis."},{"key":"BFncomms11290_CR34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1086\/590185","volume":"198","author":"T Hawkridge","year":"2008","unstructured":"Hawkridge, T. et al. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa. J. Infect. Dis. 198, 544\u2013552 (2008).","journal-title":"J. Infect. Dis."},{"key":"BFncomms11290_CR35","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1038\/nm1128","volume":"10","author":"H McShane","year":"2004","unstructured":"McShane, H. et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med. 10, 1240\u20131244 (2004).","journal-title":"Nature Med."},{"key":"BFncomms11290_CR36","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1093\/infdis\/jir195","volume":"203","author":"TJ Scriba","year":"2011","unstructured":"Scriba, T. J. et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants. J. Infect. Dis. 203, 1832\u20131843 (2011).","journal-title":"J. Infect. Dis."},{"key":"BFncomms11290_CR37","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0962-8479(05)80013-9","volume":"76","author":"U Beyazova","year":"1995","unstructured":"Beyazova, U., Rota, S., Cevheroglu, C. & Karsligil, T. Humoral immune response in infants after BCG vaccination. Tuber. Lung Dis. 76, 248\u2013253 (1995).","journal-title":"Tuber. Lung Dis."},{"key":"BFncomms11290_CR38","doi-asserted-by":"publisher","first-page":"15520","DOI":"10.1073\/pnas.1404386111","volume":"111","author":"GM Knight","year":"2014","unstructured":"Knight, G. M. et al. Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc. Natl Acad. Sci. USA 111, 15520\u201315525 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms11290_CR39","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1128\/CVI.00128-14","volume":"21","author":"SA Harris","year":"2014","unstructured":"Harris, S. A. et al. Process of assay selection and optimization for the study of case and control samples from a phase IIb efficacy trial of a candidate tuberculosis vaccine, MVA85A. Clin. Vaccine Immunol. 21, 1005\u20131011 (2014).","journal-title":"Clin. Vaccine Immunol."},{"key":"BFncomms11290_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1198\/000313001753272466","volume":"55","author":"L Yang","year":"2001","unstructured":"Yang, L. & Tsiatis, A. A. Efficiency study of estimators for a treatment effect in a pretest-posttest trial. Am. Stat. 55, 314\u2013321 (2001).","journal-title":"Am. Stat."}],"updated-by":[{"DOI":"10.1038\/ncomms11633","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T00:00:00Z","timestamp":1462492800000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms11290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms11290","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms11290.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T06:29:25Z","timestamp":1672813765000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms11290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFncomms11290"],"URL":"https:\/\/doi.org\/10.1038\/ncomms11290","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726281785.793546153","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,12]]},"assertion":[{"value":"21 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2016","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this Article contained an error in the spelling of the author Mark Hatherill, which was incorrectly given as Mark Hatheril. This has now been corrected in both the PDF and HTML versions of the Article.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.M. was previously a shareholder in the Oxford-Emergent Tuberculosis Consortium (OETC), a joint venture established for the development of MVA85A (OETC no longer exists). The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11290"}}